A cross-sectional study on the nasopharyngeal microbiota of individuals with SARS-CoV-2 infection across three COVID-19 waves in India
暂无分享,去创建一个
Divya Tej Sowpati | Mohammed M. Haque | Anirban Dutta | O. Turriziani | S. Mande | S. Soltani | Assunta Sellitto | A. B. Siva | Harrisham Kaur | Binuja Varma | K. Tallapaka | Varnali Acharya | Maurizio Sanguinetti | Tungadri Bose | Tulasi Nagabandi | Nishal Kumar Pinna | Manish Ranjan | Assunta Sellitto | Wasimuddin | Jandhyala SaiKrishna | Ombretta Turriziani | Saber Soltani | Maurizio Sanguinetti | Ombretta Turriziani | Saber Soltani | K. B. Tallapaka
[1] M. Joshi,et al. Nasopharyngeal microbiome of COVID-19 patients revealed a distinct bacterial profile in deceased and recovered individuals , 2022, Microbial Pathogenesis.
[2] N. Xu,et al. Global prevalence, treatment and outcome of tuberculosis and COVID-19 coinfection: a systematic review and meta-analysis (from November 2019 to March 2021) , 2022, BMJ Open.
[3] R. Pandey,et al. Increased Abundance of Achromobacter xylosoxidans and Bacillus cereus in Upper Airway Transcriptionally Active Microbiome of COVID-19 Mortality Patients Indicates Role of Co-Infections in Disease Severity and Outcome , 2022, Microbiology spectrum.
[4] D. Raoult,et al. Profile of the Nasopharyngeal Microbiota Affecting the Clinical Course in COVID-19 Patients , 2022, Frontiers in Microbiology.
[5] D. Kar,et al. Prevalence of Elizabethkingia meningoseptica Infections and their Resistant Pattern in Tertiary Care Hospital , 2022, Journal of Pure and Applied Microbiology.
[6] Fangfang Zhou,et al. Alterations in microbiota of patients with COVID-19: potential mechanisms and therapeutic interventions , 2022, Signal Transduction and Targeted Therapy.
[7] C. Steves,et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study , 2022, The Lancet.
[8] A. Skrahina,et al. Tuberculosis Co-Infection Is Common in Patients Requiring Hospitalization for COVID-19 in Belarus: Mixed-Methods Study , 2022, International journal of environmental research and public health.
[9] C. Lee,et al. Nosocomial septicemia in COVID-19 nosocomial K. pneumoniae, A. baumannii, and Elizabethkingia meningoseptica septicemia in a patient of COVID-19 , 2022, Journal of Infection.
[10] A. Weisz,et al. NGS analysis of nasopharyngeal microbiota in SARS-CoV-2 positive patients during the first year of the pandemic in the Campania Region of Italy , 2022, Microbial Pathogenesis.
[11] Yonglin Shi,et al. Characterization of Altered Oropharyngeal Microbiota in Hospitalized Patients With Mild SARS-CoV-2 Infection , 2022, Frontiers in Cellular and Infection Microbiology.
[12] H. Tun,et al. Gut microbiota composition is associated with SARS-CoV-2 vaccine immunogenicity and adverse events , 2022, Gut.
[13] E. Gratacós,et al. Nasopharyngeal microbiota profiling of pregnant women with SARS-CoV-2 infection , 2022, Scientific Reports.
[14] K. To,et al. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells , 2021, Emerging microbes & infections.
[15] K. Jani,et al. Nasopharyngeal microbiome reveals the prevalence of opportunistic pathogens in SARS-CoV-2 infected individuals and their association with host types , 2021, Microbes and Infection.
[16] P. Rougé,et al. Man-Specific Lectins from Plants, Fungi, Algae and Cyanobacteria, as Potential Blockers for SARS-CoV, MERS-CoV and SARS-CoV-2 (COVID-19) Coronaviruses: Biomedical Perspectives , 2021, Cells.
[17] M. Shi,et al. Association between the nasopharyngeal microbiome and metabolome in patients with COVID-19 , 2021, Synthetic and Systems Biotechnology.
[18] J. Lavigne,et al. A New Look at the Genus Solobacterium: A Retrospective Analysis of Twenty-Seven Cases of Infection Involving S. moorei and a Review of Sequence Databases and the Literature , 2021, Microorganisms.
[19] Mohammad Samir Uzzaman,et al. SARS-CoV-2 infection reduces human nasopharyngeal commensal microbiome with inclusion of pathobionts , 2021, Scientific Reports.
[20] M. Aguero-Rosenfeld,et al. SARS‐CoV‐2 antibodies: IgA correlates with severity of disease in early COVID‐19 infection , 2021, Journal of medical virology.
[21] S. Sadeghi,et al. Chitin and chitosan as tools to combat COVID-19: A triple approach , 2021, International Journal of Biological Macromolecules.
[22] Y. Haberman,et al. SARS-CoV-2 does not have a strong effect on the nasopharyngeal microbial composition , 2021, Scientific Reports.
[23] Rebecca L. Lamason,et al. The enigmatic biology of rickettsiae: recent advances, open questions and outlook , 2021, Pathogens and disease.
[24] G. Castaldo,et al. Nasopharyngeal Microbiome Signature in COVID-19 Positive Patients: Can We Definitively Get a Role to Fusobacterium periodonticum? , 2021, Frontiers in Cellular and Infection Microbiology.
[25] M. Copetti,et al. Investigation of Nasal/Oropharyngeal Microbial Community of COVID-19 Patients by 16S rDNA Sequencing , 2021, International journal of environmental research and public health.
[26] K. Chow,et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19 , 2021, Gut.
[27] T. Fatma,et al. Exploring algae and cyanobacteria as a promising natural source of antiviral drug against SARS-CoV-2 , 2020, Biomedical Journal.
[28] M. López-Pérez,et al. Nasopharyngeal Microbial Communities of Patients Infected With SARS-CoV-2 That Developed COVID-19 , 2020, bioRxiv.
[29] R. Colwell,et al. Metagenomic Next-Generation Sequencing of Nasopharyngeal Specimens Collected from Confirmed and Suspect COVID-19 Patients , 2020, mBio.
[30] S. Khatiwada,et al. Lung microbiome and coronavirus disease 2019 (COVID-19): Possible link and implications , 2020, Human Microbiome Journal.
[31] M. Farzan,et al. Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2 , 2020, bioRxiv.
[32] Zigui Chen,et al. Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19 , 2020, Gut.
[33] A. Alnazzawi,et al. Factors Influencing Global Variations in COVID-19 Cases and Fatalities; A Review , 2020, Healthcare.
[34] Gavin M Douglas,et al. PICRUSt2 for prediction of metagenome functions , 2020, Nature Biotechnology.
[35] Teng Xu,et al. Metatranscriptomic Characterization of COVID-19 Identified A Host Transcriptional Classifier Associated With Immune Signaling , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[36] O. Rötzschke,et al. The role of IgA in COVID-19 , 2020, Brain, Behavior, and Immunity.
[37] S. Ng,et al. Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization , 2020, Gastroenterology.
[38] M. Day. Covid-19: four fifths of cases are asymptomatic, China figures indicate , 2020, BMJ.
[39] A. Giacomelli,et al. Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[40] Giuliano Rizzardini,et al. Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study , 2020, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.
[41] J. Ludvigsson. Systematic review of COVID‐19 in children shows milder cases and a better prognosis than adults , 2020, Acta paediatrica.
[42] G. Herrler,et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.
[43] S. Mande,et al. ‘NetShift’: a methodology for understanding ‘driver microbes’ from healthy and disease microbiome datasets , 2018, The ISME Journal.
[44] Z. Yuan,et al. Current knowledge and perspectives of Paenibacillus: a review , 2016, Microbial Cell Factories.
[45] J. Chun,et al. Profiling bacterial community in upper respiratory tracts , 2014, BMC Infectious Diseases.
[46] M. Sale,et al. Characterization of the nasopharyngeal microbiota in health and during rhinovirus challenge , 2014, Microbiome.
[47] William A. Walters,et al. Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample , 2010, Proceedings of the National Academy of Sciences.
[48] A. Plaut,et al. Analysis of the immunoglobulin A protease gene of Streptococcus sanguis , 1991, Infection and immunity.
[49] A. Plaut,et al. Secretory immunity and the bacterial IgA proteases. , 1981, Reviews of infectious diseases.
[50] R. Squires. Depicting , 1969, Philosophy.
[51] J. Luban. SARS-CoV-2 , 2020 .
[52] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[53] I. Saiki,et al. Anti-viral activity of sulfated chitin derivatives against Friend murine leukaemia and herpes simplex type-1 viruses. , 1993, Vaccine.